Blackstone and Boston Scientific strike $455m VITALYST deal targeting cardiogenic shock treatment by 2030
Blackstone Life Sciences has agreed to co-fund development of Boston Scientific's VITALYST temporary heart pump through a $455 million collaboration. The investment supports a strategic shift towards heart-attack-related cardiogenic shock, where established mechanical support technology has demonstrated survival benefits but significant safety risks remain.